Celgene Corporation

Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis (2020) Danese S, Neurath M, Kopoń A, Zakko SF, Simmons TC, Fogel R, Siegel CA, et al. Journal article Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials (2020) Mease PJ, Gladman DD, Gomez-Reino JJ, Hall S, Kavanaugh A, Lespessailles E, Schett G, et al. Journal article Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs (2020) Zhang M, Haughey M, Wang NY, Blease K, Kapoun AM, Couto S, Belka I, et al. Journal article Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis (2019) Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N, Teng L, et al. Journal article A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis (2019) Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, Rosenthal A, et al. Journal article Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma (2018) Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, Rosenthal A, et al. Journal article Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study (2018) Danese S, Neurath M, Kopon A, Zakko S, Simmons T, Fogel R, Maccarone J, et al. Conference contribution 5-YEAR EFFICACY AND SAFETY OF APREMILAST TREATMENT IN SUBJECTS WITH PSORIATIC ARTHRITIS: POOLED ANALYSIS OF THE PALACE STUDIES (2018) Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N, Teng L, et al. Conference contribution Durability of apremilast response through 5 years of treatment in subjects with psoriatic arthritis (2018) Kavanaugh A, Gladman DD, Gomez-Reino JJ, Hall S, Lespessailles E, Mease PJ, Schett G, et al. Conference contribution LONG-TERM (156-WEEK) IMPROVEMENTS IN DACTYLITIS AND ENTHESITIS WITH APREMILAST INPSORIATIC ARTHRITIS SUBJECTS: ANALYSIS OF A LARGE, POOLED PALACE 1-3 DATABASE (2018) Gladman DD, Kavanaugh A, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, et al. Conference contribution